Case Study: Leading HPV Vaccine Pharmaceutical Company achieves rapid HPV 16 enrollment with Elligo Health Research

Leading HPV Vaccine Pharmaceutical Company - Customer Case Study

Leading HPV Vaccine Pharmaceutical Company was struggling to enroll patients in an HPV 16 study, with only one patient enrolled months after the trial began and an 84% screen failure rate. The company needed a better way to identify patients who screened positive for HPV 16, since its existing sites could not determine HPV type before screening.

Elligo Health Research used its IntElligo® Research Stack platform and women’s health network to analyze electronic health records and lab results, quickly identifying eligible HPV 16 patients. Elligo Health Research enrolled the first patient in less than two weeks after site approval and helped the study fully enroll its first stage within the original timeline, contributing more than 90% of enrolled patients in three months while reducing screen failures by about two-thirds.